NHS funding for use of Bristol-Myers Squibb’s Opdivo as an adjuvant treatment for resected stage III and IV melanoma is being blocked by the National Institute for Health and Care Excellence.
11th September 2018
A new NHS campaign is striving to clamp down on the millions of pounds worth of prescriptions incorrectly claimed for free each year.
11th September 2018
Now in it's 25th year, the PharmaTimes Marketer of the Year competition closes for entry on Friday 14th September - take advantage of this great opportunity to compete, benchmark, learn and raise standards in pharma marketing.
10th September 2018
Napp Pharmaceuticals says the UK is the first country in Europe to launch flutiform k-haler, a breath-actuate inhaler for adolescents and adults living with asthma.
10th September 2018
AstraZeneca and Amgen’s tezepelumab has won breakthrough therapy status in the US for its potential to treat severe asthma without an eosinophilic phenotype.
10th September 2018
The MS Society has launched a petition imploring the National Institute for Health and Care Excellence, NHS England and Roche to come to an agreement on NHS availability of Ocrevus for primary progressive multiple sclerosis (PPMS).
10th September 2018
GlaxoSmithKline’s bid to expand the use of its biologic Nucala in the US to include patients with coronary pulmonary obstructive disorder (COPD) has hit a significant setback.
10th September 2018
Entry to the inaugural PharmaTimes Sales Awards - established to recognise and celebrate the very best sales professionals in the industry today - will close today.
7th September 2018
Specialist healthcare group BTG has snapped up med tech group Novate Medical in a deal potentially worth $150 million.
7th September 2018
Imperial College London, UCL and Eli Lilly have formed an alliance that strives to transform medicines manufacturing in England.
7th September 2018
The government has unveiled its ambition for the NHS to become “the most advanced health system in the world” through use of the “best innovations in new technology and artificial intelligence”.
7th September 2018
A mid-stage trial assessing Gilead and Galapagos’ JAK 1 inhibitor filgotinib in ankylosing spondylitis has hit its targets.
7th September 2018
Now in it's 25th year, the PharmaTimes Marketer of the Year competition closes for entry on Friday 14th September - make sure you take advantage of this great opportunity for you and your team to compete, benchmark, learn and raise standards in pharma marketing.
6th September 2018
US regulators have extended the review period for Roche’s application to market Tecentriq in combination with Avastin, carboplatin and paclitaxel for first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).
6th September 2018
Teva Pharmaceutical Industries has decided not to pursue development of laquinimod, and has returned rights to the drug back to Swedish group Active Biotech.
6th September 2018
